DC BeadLUMI™

VISION

With DC Bead LUMI™, you are empowered to see the location of the beads during and after LUMI-TACE

This case was impressive because of the clear visualisation of the tumour and the embolised vessels on the post-embolisation non-contrast CBCT, in addition to the complete response of the treated lesions.
Early experience user feedback

DC Bead LUMI™ visible in tumour-feeding vessels on fluoroscopy during procedure after clearance of contrast

CBCT 10 mins post procedure confirms coverage of tumour

DC Bead LUMI™ remain visible at 4-week follow-up on non contrast-enhanced CT. MRI confirms complete response of tumour (mRECIST)

PRECISIÓN

DC Bead LUMI™ are designed to offer a more precise and controlled procedure than current techniques

The radiopacity allows for accurate needle placement and full lesion ablation. With standard DC Bead™, the lesion cannot be seen on non-contrast CT and there is a possibility that the lesion may not be fully ablated.
Early experience user feedback

CT immediately post embolisation

Four days after embolisation,
DC Bead LUMI™ are visible
on non-contrast CT, allowing
for accurate needle placement

Non-contrast CT after microwave ablation demonstrates completeness of treatment

ASSURANCE

DC Bead LUMI™ offer the best opportunity to individualise your patients’ treatment

The real-time visualisation of the DC Bead LUMI™, and not a surrogate of contrast and beads, gave me confidence to see exactly where my therapy was being delivered.
Early experience user feedback

Single-shot fluoroscopy during the procedure

CBCT 10 mins post embolisation with DC Bead LUMI™

DC Bead LUMI™ remain visible on non-contrast CT at 6-week follow-up. Complete response confirmed on MRI

Descripción

  • DC Bead LUMI™ are the first-ever radiopaque drug-eluting beads.They have been developed on the same technology platform and to the same high standard as DC Bead™

Presentación y tamaños

  • DC Bead LUMI™ are available in the same presentation as DC Bead™ (2ml of beads per vial) in two calibrated size ranges. Supplied with Vialok™ vented transfer device
Size 70–150 μm 100–300 μm
Label Colour™
70–150 μm		 Black Yellow
Volume of Beads™
100–300 μm		 2ml 2ml
Product Code™
100–300 μm		 R02D001 R02D103

Los Bead LUMI™ son:

  • Inherently and consistently radiopaque with iodine evenly distributed throughout
  • Visible under all standard X-ray imaging modalities
  • Visible as they accumulate in vessels and contrast clears
  • Visible in follow-up scans due to long-lasting radiopacity
  • Approved for loading with doxorubicin and irinotecan

DC Bead LUMI™ provide increased control and optimise patient treatment strategies because they:

  • Enable real-time adjustments during procedure to guide precise delivery of beads into the tumour Enhance determination of embolisation endpoint
  • Assist in discovering regions of under treatment
  • Allow for the precise evaluation and confident reporting of the completeness of tumour treatment
  • Help inform future treatment planning

Administración

  • DC Bead LUMI™ are delivered in commonly used contrast agents without dilution and via routinely used microcatheters

Radiopacity

  • DC Bead LUMI™ are visible under all standard X-ray modalities including computed tomography [CT], cone-beam computed tomography [CBCT] and fluoroscopy
  • DC Bead LUMI™ may overcome some of the image limitations associated with current conventional TACE/DEB-TACE procedures
  • Real-time visualisation of bead delivery may allow for better control of bead location and endpoint determination
  • Potential to use follow-up imaging for tumour “marking” and to confirm location of beads, success of embolisation procedure and planning for future treatment

Duran R et al. Theranostics 2016; 6(1): 28-39
CT: Computed tomography

Drug Loading and Elution

  • Approved for loading with doxorubicin and irinotecan
  • In-vitro testing confirms that the controlled and sustained elution profiles of drug from DC Bead LUMI™are comparable to those achieved with DC Bead™
    • Elution of doxorubicin and irinotecan falls within the same window as DC Bead™1
    • Under the same conditions, both DC Bead LUMI™ and DC Bead™ achieve complete elution of doxorubicin and irinotecan1,2
  • DC Bead LUMI™ do not reduce in diameter when loaded with drug
  1. Swaine TS et al. Poster presentation APS meeting, Nottingham, UK. September 2015.
  2. Data on file (FAR-ES-0121) at Biocompatibles UK